Simultaneous RNA quantification of human and retroviral genomes reveals intact interferon signaling in HTLV-1-infected CD4+ T cell lines

Virology Journal

Volumn 9, Issue , 2012, Pages

  Moens, Britta ^a   Pannecouque, Christophe ^a   Lápez, Giovanni ^b   Talledo, Michael ^b   Gotuzzo, Eduardo ^b,c   Khouri, Ricardo ^a,d   Bittencourt, Achiléa ^e   Farré, Lourdes ^d   Galvão Castro, Bernardo ^d,f   Vandamme, Anne Mieke ^a,g   Van Weyenbergh, Johan ^a,d,h  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b INSTITUTO DE MEDICINA TROPICAL ALEXANDER VON HUMBOLDT   (Peru)

^c UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^f ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^g INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^h Institute for Investigation in Immunology INCT   (Brazil)

Author keywords

Antiviral activity; HIV 1; HTLV 1; IFN ; IFN signaling; Retrovirus

Indexed keywords

ALPHA INTERFERON; GAG PROTEIN; MESSENGER RNA; PROTEIN P19; RNA; TRANSCRIPTOME; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL LEVEL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLOW CYTOMETRY; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 1; IC 50; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PROTEIN SECRETION; RNA ANALYSIS; TRANSACTIVATION; VIRUS GENOME; VIRUS INHIBITION;

CD4-POSITIVE T-LYMPHOCYTES; CELL SURVIVAL; GENE EXPRESSION PROFILING; HIV-1; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; INTERFERON-ALPHA; RNA; SIGNAL TRANSDUCTION;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 1;

EID: 84865277356     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-9-171     Document Type: Article

References (74)

1. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. Verdonck K, Gonzalez E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E, Lancet Infect Dis 2007 7 4 266 281 10.1016/S1473-3099(07)70081-6 17376384
2. The first postmodern pandemic: 25years of HIV/AIDS. Kallings LO, J Intern Med 2008 263 3 218 243 10.1111/j.1365-2796.2007.01910.x 18205765
3. Antiretroviral drugs. De Clercq E, Curr Opin Pharmacol 2010 10 5 507 515 10.1016/j.coph.2010.04.011 20471318
4. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A, de The G, Lancet 1985 2 8452 407 410 2863442
5. Epidemiological features of HTLV-I and adult T cell leukemia. Tajima K, Cartier L, Intervirology 1995 38 3-4 238 246 8682622
6. O'Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T: Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W, J Clin Oncol 2009 27 3 453 459 19064971
7. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O, J Clin Oncol 2010 28 27 4177 4183 10.1200/JCO.2010.28.0669 20585095
8. HTLV-I associated myelopathy, a new clinical entity. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M, Lancet 1986 1 8488 1031 1032 2871307
9. HTLV-I-associated myelopathy. Izumo S, Umehara F, Osame M, Neuropathology 2000 20 Suppl 65 S68 11037191
10. Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis. Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H, Izumo S, Arimura K, Osame M, J Neurovirol 1996 2 5 345 355 10.3109/13550289609146899 8912211
11. FAS-670A/G single nucleotide polymorphism may be associated with human T lymphotropic virus-1 infection and clinical evolution to TSP/HAM. Vallinoto AC, Santana BB, dos Santos EL, Santo RR, Hermes RB, Sousa RC, Cayres-Vallinoto I, Machado LF, Ishak MO, Ishak R, Virus Res 2012 163 1 178 182 10.1016/j.virusres. 2011.09.015 21971214
12. Fas 670 promoter polymorphism is associated to susceptibility, clinical presentation, and survival in adult T cell leukemia. Farre L, Bittencourt AL, Silva-Santos G, Almeida A, Silva AC, Decanine D, Soares GM, Alcantara LC, Van Dooren S, Galvão-Castro B, Vandamme AM, Van Weyenbergh J, J Leukoc Biol 2008 83 1 220 222 17962369
13. Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial. Lane HC, Davey V, Kovacs JA, Feinberg J, Metcalf JA, Herpin B, Walker R, Deyton L, Davey RT, Falloon J, et al. Ann Intern Med 1990 112 11 805 811 1971503
14. Virus interference. Isaacs A, Lindenmann J, I. The interferon. Proc R Soc Lond B Biol Sci 1957 147 927 258 267 10.1098/rspb.1957.0048
15. Interferon signalling network in innate defence. Takaoka A, Yanai H, Cell Microbiol 2006 8 6 907 922 10.1111/j.1462-5822.2006.00716.x 16681834
16. Mechanisms of type-I- and type-II-interferon-mediated signalling. Platanias LC, Nat Rev Immunol 2005 5 5 375 386 10.1038/nri1604 15864272
17. The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Taniguchi T, Takaoka A, Curr Opin Immunol 2002 14 1 111 116 10.1016/S0952- 7915(01)00305-3 11790540
18. Type I interferon: friend or foe? Trinchieri G, J Exp Med 2010 207 10 2053 2063 10.1084/jem.20101664 20837696
19. Functional classification of interferon-stimulated genes identified using microarrays. de Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM, Silverman RH, Williams BR, J Leukoc Biol 2001 69 6 912 920 11404376
20. Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells. Goujon C, Malim MH, J Virol 2010 84 18 9254 9266 10.1128/JVI.00854-10 20610724
21. Interferons at age 50: past, current and future impact on biomedicine. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR, Nat Rev Drug Discov 2007 6 12 975 990 10.1038/nrd2422 18049472
22. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: A pilot study. King JK, Yeh SH, Lin MW, Liu CJ, Lai MY, Kao JH, Chen DS, Chen PJ, Hepatology 2002 36 6 1416 1424 12447867
23. Regulation of PKR and IRF-1 during hepatitis C virus RNA replication. Pflugheber J, Fredericksen B, Sumpter R, Wang C, Ware F, Sodora DL, Gale M, Proc Natl Acad Sci USA 2002 99 7 4650 4655 10.1073/pnas.062055699 11904369
24. Hairy cell leukemia: treatment successes in the past 25years. Golomb HM, J Clin Oncol 2008 26 16 2607 2609 10.1200/JCO.2007.15.7420 18509168
25. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J, N Engl J Med 2002 347 13 975 982 10.1056/NEJMoa020047 12324553
26. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Ferrantini M, Capone I, Belardelli F, Biochimie 2007 89 6-7 884 893 17532550
27. Present role and future potential of type I interferons in adjuvant therapy of high-risk operable melanoma. Moschos S, Kirkwood JM, Cytokine Growth Factor Rev 2007 18 5-6 451 458 17693125
28. Complex modulation of cell type-specific signaling in response to type I interferons. van Boxel-Dezaire AH, Rani MR, Stark GR, Immunity 2006 25 3 361 372 10.1016/j.immuni.2006.08.014 16979568
29. Interferon-based therapy of hepatitis C. Chevaliez S, Pawlotsky JM, Adv Drug Deliv Rev 2007 59 12 1222 1241 10.1016/j.addr.2007.07.002 17869375
30. Interferons, interferon-like cytokines, and their receptors. Pestka S, Krause CD, Walter MR, Immunol Rev 2004 202 8 32 10.1111/j.0105-2896.2004.00204.x 15546383
31. A diverse range of gene products are effectors of the type I interferon antiviral response. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM, Nature 2011 472 7344 481 485 10.1038/nature09907 21478870
32. Interferon inhibits the replication of HIV-1, SIV, and SHIV chimeric viruses by distinct mechanisms. Korth MJ, Taylor MD, Katze MG, Virology 1998 247 2 265 273 10.1006/viro.1998.9249 9705919
33. Activity of interferons alpha, beta, and gamma against human immunodeficiency virus replication in vitro. Hartshorn KL, Neumeyer D, Vogt MW, Schooley RT, Hirsch MS, AIDS Res Hum Retroviruses 1987 3 2 125 133 10.1089/aid.1987.3.125 3113463
34. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Okumura A, Lu G, Pitha-Rowe I, Pitha PM, Proc Natl Acad Sci USA 2006 103 5 1440 1445 10.1073/pnas.0510518103 16434471
35. Interferon treatment inhibits virus replication in HIV-1- and SIV-infected CD4+ T-cell lines by distinct mechanisms: evidence for decreased stability and aberrant processing of HIV-1 proteins. Agy MB, Acker RL, Sherbert CH, Katze MG, Virology 1995 214 2 379 386 10.1006/viro.1995.0047 8553538
36. Alpha interferon-induced antiretroviral activities: restriction of viral nucleic acid synthesis and progeny virion production in human immunodeficiency virus type 1-infected monocytes. Baca-Regen L, Heinzinger N, Stevenson M, Gendelman HE, J Virol 1994 68 11 7559 7565 7933143
37. Specific inhibition of viral protein synthesis in HIV-infected cells in response to interferon treatment. Coccia EM, Krust B, Hovanessian AG, J Biol Chem 1994 269 37 23087 23094 7521875
38. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB, J Interferon Res 1986 6 2 143 152 10.1089/jir.1986.6.143 2425014
39. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB, Nat Med 2008 14 10 1077 1087 10.1038/nm.1871 18806803
40. Genome-wide mRNA expression correlates of viral control in CD4+ T-cells from HIV-1-infected individuals. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Gunthard HF, Goldstein DB, Telenti A, PLoS Pathog 2010 6 2 1000781 10.1371/journal.ppat.1000781 20195503
41. Interferon-alpha and tumor necrosis factor-alpha in serum of patients in various stages of HIV-1 infection. von Sydow M, Sonnerborg A, Gaines H, Strannegard O, AIDS Res Hum Retroviruses 1991 7 4 375 380 10.1089/aid.1991.7.375 1906289
42. Active anti-interferon-alpha immunization: a European-Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study). Gringeri A, Musicco M, Hermans P, Bentwich Z, Cusini M, Bergamasco A, Santagostino E, Burny A, Bizzini B, Zagury D, J Acquir Immune Defic Syndr Hum Retrovirol 1999 20 4 358 370 10.1097/00042560-199904010-00006 10096580
43. HIV-1 immunopathogenesis: how good interferon turns bad. Herbeuval JP, Shearer GM, Clin Immunol 2007 123 2 121 128 10.1016/j.clim.2006.09.016 17112786
44. A randomized trial of interferon alpha therapy for HIV type 1 infection. Haas DW, Lavelle J, Nadler JP, Greenberg SB, Frame P, Mustafa N, St Clair M, McKinnis R, Dix L, Elkins M, Rooney J, AIDS Res Hum Retroviruses 2000 16 3 183 190 10.1089/088922200309278 10710206
45. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. Asmuth DM, Murphy RL, Rosenkranz SL, Lertora JJ, Kottilil S, Cramer Y, Chan ES, Schooley RT, Rinaldo CR, Thielman N, Li XD, Wahl SM, Shore J, Janik J, Lempicki RA, Simpson Y, Pollard RB, J Infect Dis 2010 201 11 1686 1696 10.1086/652420 20420510
46. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. Hatzakis A, Gargalianos P, Kiosses V, Lazanas M, Sypsa V, Anastassopoulou C, Vigklis V, Sambatakou H, Botsi C, Paraskevis D, Stalgis C, J Interferon Cytokine Res 2001 21 10 861 869 10.1089/107999001753238114 11710999
47. Alpha interferon inhibits human T-cell leukemia virus type 1 assembly by preventing Gag interaction with rafts. Feng X, Heyden NV, Ratner L, J Virol 2003 77 24 13389 13395 10.1128/JVI.77.24.13389-13395.2003 14645593
48. Human T-cell leukemia virus type 1 blunts signaling by interferon alpha. Feng X, Ratner L, Virology 2008 374 1 210 216 10.1016/j.virol.2007.12.036 18234266
49. Human T-cell leukemia virus type 1 Tax modulates interferon-alpha signal transduction through competitive usage of the coactivator CBP/p300. Zhang J, Yamada O, Kawagishi K, Araki H, Yamaoka S, Hattori T, Shimotohno K, Virology 2008 379 2 306 313 10.1016/j.virol.2008.06.035 18678383
50. HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). Oliere S, Hernandez E, Lezin A, Arguello M, Douville R, Nguyen TL, Olindo S, Panelatti G, Kazanji M, Wilkinson P, Sekaly RP, Cesaire R, Hiscott J, PLoS Pathog 2010 6 11 1001177 10.1371/journal.ppat.1001177 21079688
51. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. N Engl J Med 1995 332 26 1744 1748 10.1056/NEJM199506293322603 7760890
52. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y, Araki S, Mori M, Nagataki S, Matsukura S, Akamine T, Nakagawa M, Yamamoto I, Osame M, Neurology 1996 46 4 1016 1021 10.1212/WNL.46.4.1016 8780082
53. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20years later. Pannecouque C, Daelemans D, De Clercq E, Nat Protoc 2008 3 3 427 434 10.1038/nprot.2007.517 18323814
54. Ascorbic Acid Has Superior Ex Vivo Antiproliferative, Cell Death-Inducing and Immunomodulatory Effects over IFN- in HTLV-1-Associated Myelopathy. Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G, Lopez G, Alvarez C, Talledo M, Gotuzzo E, de Almeida Kruschewsky R, Galvão-Castro B, Vandamme AM, Van Weyenbergh J, PLoS Negl Trop Dis 2012 6 7 1729 10.1371/journal.pntd.0001729 22848768
55. Systems Biology Approaches Reveal a Specific Interferon-Inducible Signature in HTLV-1 Associated Myelopathy. Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP, McNab FW, O'Garra A, Taylor GP, Bangham CR, PLoS Pathog 2012 8 1 1002480 10.1371/journal.ppat.1002480 22291590
56. Direct multiplexed measurement of gene expression with color-coded probe pairs. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, Dimitrov K, Nat Biotechnol 2008 26 3 317 325 10.1038/nbt1385 18278033
57. New insights into the role of RNase L in innate immunity. Chakrabarti A, Jha BK, Silverman RH, J Interferon Cytokine Res 2011 31 1 49 57 10.1089/jir.2010.0120 21190483
58. Human T cell leukemia virus type 1 Tax inhibits innate antiviral signaling via NF-kappaB-dependent induction of SOCS1. Charoenthongtrakul S, Zhou Q, Shembade N, Harhaj NS, Harhaj EW, J Virol 2011 85 14 6955 6962 10.1128/JVI.00007-11 21593151
59. Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. Sharma S, Grandvaux N, Mamane Y, Genin P, Azimi N, Waldmann T, Hiscott J, J Immunol 2002 169 6 3120 3130 12218129
60. Possible involvement of interferon regulatory factor 4 (IRF4) in a clinical subtype of adult T-cell leukemia. Imaizumi Y, Kohno T, Yamada Y, Ikeda S, Tanaka Y, Tomonaga M, Matsuyama T, Jpn J Cancer Res 2001 92 12 1284 1292 10.1111/j.1349-7006.2001.tb02151.x 11749693
61. IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Ramos JC, Ruiz P, Ratner L, Reis IM, Brites C, Pedroso C, Byrne GE, Toomey NL, Andela V, Harhaj EW, Lossos IS, Harrington WJ, Blood 2007 109 7 3060 3068 17138822
62. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Platanias LC, Pharmacol Ther 2003 98 2 129 142 10.1016/S0163-7258(03)00016-0 12725866
63. Coinfection by HIV-1 and human lymphotropic virus type 1 in Brazilian children is strongly associated with a shorter survival time. Pedroso C, Netto EM, Weyll N, Brites C, J Acquir Immune Defic Syndr 2011 57 Suppl 3 208 S211 21857320
64. Coinfection with human T-cell lymphotropic virus type I and HIV in Brazil. Impact on markers of HIV disease progression. Schechter M, Harrison LH, Halsey NA, Trade G, Santino M, Moulton LH, Quinn TC, JAMA 1994 271 5 353 357 10.1001/jama.1994.03510290035033 7904317
65. HIV/human T-cell lymphotropic virus coinfection revisited: impact on AIDS progression. Brites C, Sampalo J, Oliveira A, AIDS Rev 2009 11 1 8 16 19290030
66. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients. Van Weyenbergh J, Lipinski P, Abadie A, Chabas D, Blank U, Liblau R, Wietzerbin J, J Immunol 1998 161 3 1568 1574 9686625
67. HTLV in the Americas: challenges and perspectives. Carneiro-Proietti AB, Catalan-Soares BC, Castro-Costa CM, Murphy EL, Sabino EC, Hisada M, Galvao-Castro B, Alcantara LC, Remondegui C, Verdonck K, Proietti FA, Rev Panam Salud Publica 2006 19 1 44 53 10.1590/S1020-49892006000100007 16536938
68. Transformation of normal human cord lymphocytes by co-cultivation with a lethally irradiated human T-cell line carrying type C virus particles. Miyoshi I, Yoshimoto S, Kubonishi I, Taguchi H, Shiraishi Y, Ohtsuki Y, Akagi T, Gann 1981 72 6 997 998 6281121
69. Restricted expression of human T-cell leukemia-lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Salahuddin SZ, Markham PD, Wong-Staal F, Franchini G, Kalyanaraman VS, Gallo RC, Virology 1983 129 1 51 64 10.1016/0042-6822(83)90395-1 6412453
70. A T-cell line derived from normal human cord leukocytes by co-culturing with human leukemic T-cells. Miyoshi I, Kubonishi I, Yoshimoto S, Shiraishi Y, Gann 1981 72 6 978 981 6281119
71. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Harada S, Koyanagi Y, Yamamoto N, Science 1985 229 4713 563 566 10.1126/science.2992081 2992081
72. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Popovic M, Sarngadharan MG, Read E, Gallo RC, Science 1984 224 4648 497 500 10.1126/science.6200935 6200935
73. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. Pauwels R, Balzarini J, Baba M, Snoeck R, Schols D, Herdewijn P, Desmyter J, De Clercq E, J Virol Methods 1988 20 4 309 321 10.1016/0166-0934(88)90134-6 2460479
74. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bolstad BM, Irizarry RA, Astrand M, Speed TP, Bioinformatics 2003 19 2 185 193 10.1093/bioinformatics/19.2.185 12538238